Minnesota

No — Minnesota allows asynchronous-first care under the Minnesota Telehealth Act. A Minnesota-licensed provider can review your intake by secure message and prescribe semaglutide without a scheduled video call, provided the standard of care is met. Your provider may request a video visit or additional information only if your history calls for it.

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A Minnesota-licensed clinician reviews it, and because Minnesota allows asynchronous-first care for non-controlled medications like GLP-1s under the Minnesota Telehealth Act, that review can happen by secure message without a scheduled video call, unless your history calls for one. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Minnesota address in a few business days.

The process is the same as for semaglutide — complete Pallas's online intake, and a Minnesota-licensed clinician reviews it, asynchronously in most cases, since Minnesota allows telehealth providers to establish care and prescribe without a live video visit when the standard of care is met. If appropriate, your clinician can prescribe compounded tirzepatide, prepared per-patient by a US-licensed §503A compounding pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide and tirzepatide are legal and available to eligible Minnesota residents through licensed telehealth. Both are prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a Minnesota-licensed clinician must prescribe them based on a documented, patient-specific clinical rationale. Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies and serves Minnesota with free shipping, arriving within 2–3 business days — fastest to Minneapolis, Saint Paul, and the metro suburbs, with Duluth, the Iron Range, and rural northern ZIP codes sometimes taking an extra day. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Nurse practitioners licensed in Minnesota can prescribe semaglutide and tirzepatide via telehealth when acting within their state scope of practice. Every Pallas prescription for a Minnesota patient is written by licensed prescribers — physicians and, within their scope of practice, nurse practitioners and physician assistants — each holding an active Minnesota license.

Several licensed telehealth platforms serve Minnesota residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in Minnesota, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Minnesota residents and is LegitScript Healthcare Merchant Certified.

Minnesota Medical Assistance covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited and step therapy applies. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medical Assistance coverage does not apply to our prescriptions.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Minnesota address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in the Twin Cities, Duluth, or a rural Minnesota ZIP code.

Eligibility is always decided by a Minnesota-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Minnesota-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Minnesota-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Minnesota Board of Medical Practice reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Minnesota address, usually within a few business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Minnesota address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Minnesota address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Minnesota patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Minnesota during intake.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Minnesota weighs your history, goals, and budget to recommend a starting point.